查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103548

惡性間皮癌市場：全球市場預測，2026-2032年

Malignant Mesothelioma Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，惡性間皮癌市場規模將達到 13.0725 億美元，複合年成長率為 8.41%。

主要市場統計數據
基準年 2025 7.4267億美元
預計年份：2026年 8.0238億美元
預測年份：2032年 13.0725億美元
複合年成長率 (%) 8.41%

惡性間皮癌執行摘要

惡性間皮癌是一種高度侵襲性的癌症，主要發生於胸膜，與先前石棉暴露密切相關，通常有數十年的潛伏期。儘管許多地區已限制或禁止使用石棉，但由於既往職業暴露、環境暴露以及在拆除、拆船、採礦、建築和工業維護工作中的暴露，仍有新的病例報告。由於其早期症狀特異性、常在晚期才被發現、病理複雜且長期生存率低，該疾病仍然是一個臨床上極具挑戰性的難題。

惡性間皮癌臨床實踐的變革性變化

惡性間皮癌的治療格局正在經歷一場變革性的轉變，從基於症狀的診斷轉向整合影像學、組織學確診、病理檢查、分子檢測和多學科腫瘤委員會評估的循證臨床診療模式。儘管胸部腫瘤學的進步提高了免疫查核點抑制劑在合格的患者中的應用，但化療、手術、放射線治療和支持治療仍然根據疾病分期、組織學類型、患者身體狀況和專科醫生的評估而繼續使用。區分上皮型、肉瘤樣型和雙相型組織學類型仍然至關重要，因為組織學亞型與治療反應和預後密切相關。

人工智慧對惡性間皮癌的累積影響

人工智慧正在對惡性間皮癌的診斷、治療計畫、檢查和後續觀察等各個方面產生累積影響。在放射學領域，人工智慧驅動的影像分析可以輔助利用CT和其他影像學方法檢測胸膜異常，量化腫瘤負荷，並評估治療反應，尤其是在病灶形態瀰漫且難以測量的情況下。在病理學領域，電腦輔助工具可以輔助進行數位切片閱片、模式識別和品質保證，但由病理專家進行確認仍然至關重要，因為間皮瘤的診斷需要仔細整合形態學、免疫表現型和臨床背景。

惡性間皮癌的關鍵區域性見解

在亞太地區，惡性間皮癌的發病趨勢與各地不同的石棉控制措施、快速的城市重建、先前的工業暴露以及該地區部分地區的造船和拆船活動密切相關。雖然澳洲和日本早已認知到石棉相關疾病，但中國、印度、韓國和東南亞各國的診斷能力、職業暴露監測以及採取糾正措施的準備情況卻存在差異。隨著腫瘤基礎設施的完善，影像學、病理學和系統性治療的可近性正在提高，但在職業暴露史追蹤不完善的地區，漏診仍然是一個令人擔憂的問題。

惡性間皮癌的主要群體分析

北約成員國對軍艦、基地、老舊設施中的石棉問題以及退伍軍人的石棉暴露史都抱有通用的擔憂，因此，與國防相關的監測、糾正措施、暴露記錄以及醫療保健服務是惡性間皮癌政策和治療的關鍵要素。協調一致的設施檢查、退伍軍人健康監測以及老舊國防基礎設施的安全維護工作，將有助於減少可預防的石棉暴露，並支持及時診斷。

各國惡性間皮癌概況

中國的惡性間皮癌現狀受到大規模工業活動、城市改造以及提高職業暴露意識和規範專業診斷的迫切需求的影響。在美國，惡性間皮癌的醫療體系較為完善，擁有專業的癌症中心、臨床實驗室、石棉暴露記錄和職業安全監管體系；然而，老舊建築、造船廠、工業場所和軍事設施中殘留的石棉仍然是一個重大挑戰。在日本，人們對石棉相關疾病的認知已經相當深入，並擁有先進的腫瘤診療服務，但對既往接觸過石棉的人仍需持續監測。印度在建材中使用石棉、工人保護以及透過病理檢查獲得確診等方面面臨嚴峻挑戰，尤其是在大城市以外的地區。

為行業領導者提供的實用建議

產業領導者應優先考慮早期診斷，加強從基層醫療、呼吸內科、職業醫學和急診到胸腔腫瘤專科團隊的訊息傳播管道。標準化的診斷方案應包括詳細的職業和環境暴露史、高品質的影像學檢查、專家病理學評估、免疫組織化學檢測以及適當的分子檢測，從而提高診斷的準確性和治療方案製定的精準性。

調查方法

本執行摘要基於系統性的二手研究方法，採用公開可查且可驗證的資訊來源，包括癌症登記資料、職業健康指南、同行評審的醫學文獻、臨床實踐調查方法、政府石棉法規、公共衛生機構資料以及國際癌症和職業健康資源。檢驗優先考慮符合以下條件的：已確立的臨床共識、已記錄的石棉暴露途徑、檢驗的診斷方法、公認的治療標準或當地監管和醫療保健基礎設施因素。

結論

由於惡性間皮癌從接觸石棉到發病潛伏期長、診斷複雜且疾病進行性，因此它仍然是腫瘤學和職業健康領域面臨的一項緊迫挑戰。儘管監管措施已在許多地區減少了新的石棉使用，但由於過去使用遺留的石棉、監管措施執行不力以及監測不足，全球疾病負擔仍然存在。免疫療法、病理學、影像學、真實世界數據以及人工智慧驅動的工作流程的進步正在提高檢測、分類和管理該疾病的能力，但患者的預後仍然很大程度上取決於早期發現病情以及能否獲得經驗豐富的多學科團隊的診治。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：惡性間皮癌市場：依疾病類型分類

  • 胸膜間皮瘤
  • 腹膜間皮瘤
  • 心包膜間皮瘤
  • 鞘膜間皮瘤

第8章：惡性間皮癌市場：依治療類型分類

  • 化療
  • 免疫療法
  • 標靶治療
  • 細胞療法
  • 基因治療
  • 用於腫瘤治療的電場
  • 放射線治療

第9章：惡性間皮癌市場：依藥物類別分類

  • 抗葉酸
  • 鉑類藥物
  • 免疫查核點抑制劑
  • 單株抗體
  • 細胞和基因治療

第10章：惡性間皮癌市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第11章：惡性間皮癌市場：依最終用戶分類

  • 醫院
  • 癌症中心
  • 專科腫瘤診所
  • 大學醫院
  • 研究機構

第12章惡性間皮癌市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：惡性間皮癌市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章惡性間皮癌市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Amgen Inc.
  • AstraZeneca PLC
  • Atara BIoTherapeutics, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • Cartesian Therapeutics, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK plc
  • Merck & Co., Inc.
  • Novocure Ltd.
  • Pfizer Inc.
  • SELLAS Life Sciences Group, Inc.
  • Sensei BIoTherapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-C002B1C99564

The Malignant Mesothelioma Market is projected to grow by USD 1,307.25 million at a CAGR of 8.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 742.67 million
Estimated Year [2026] USD 802.38 million
Forecast Year [2032] USD 1,307.25 million
CAGR (%) 8.41%

Malignant Mesothelioma Executive Summary

Malignant mesothelioma is an aggressive cancer most often arising in the pleura and strongly associated with prior asbestos exposure, with a long latency period that commonly spans decades. Although asbestos use has been restricted or banned in many jurisdictions, new diagnoses continue because of historical occupational exposure, environmental exposure, and exposure during demolition, shipbreaking, mining, construction, and industrial maintenance. The disease remains clinically challenging due to nonspecific early symptoms, late-stage presentation, complex pathology, and limited long-term survival outcomes.

The malignant mesothelioma landscape is being shaped by earlier diagnostic pathways, multidisciplinary care, biomarker-enabled treatment selection, immunotherapy adoption, and stronger public health surveillance. Key industry-specific priorities include pleural mesothelioma diagnosis, peritoneal mesothelioma management, asbestos-related disease monitoring, thoracic oncology services, clinical trial access, occupational health compliance, and real-world evidence generation. Stakeholders across healthcare delivery, diagnostics, therapeutics, environmental safety, and worker protection are increasingly focused on improving time to diagnosis, expanding access to specialist centers, and aligning treatment decisions with evolving clinical evidence.

Transformative Shifts in the Malignant Mesothelioma Landscape

The malignant mesothelioma landscape is undergoing transformative shifts as care moves from symptom-led diagnosis toward integrated, evidence-based pathways that combine imaging, tissue confirmation, pathology review, molecular testing, and multidisciplinary tumor board assessment. Advances in thoracic oncology have elevated the role of immune checkpoint inhibitors in eligible patients, while chemotherapy, surgery, radiotherapy, and supportive care continue to be used based on disease stage, histology, patient fitness, and specialist evaluation. The distinction between epithelioid, sarcomatoid, and biphasic histology remains critical because histologic subtype is linked to treatment responsiveness and prognosis.

Diagnostic transformation is also accelerating. Immunohistochemistry panels are used to differentiate mesothelioma from metastatic carcinomas, while molecular and cytogenetic markers such as BAP1 loss and CDKN2A deletion can support diagnosis in appropriate clinical contexts. At the same time, occupational and environmental health regulations are influencing disease prevention, with bans or restrictions on asbestos, stricter workplace exposure limits, and remediation protocols. However, legacy asbestos in buildings, industrial assets, and ships remains a persistent risk, making surveillance, safe abatement, and exposure documentation essential components of the broader malignant mesothelioma ecosystem.

Cumulative Impact of Artificial Intelligence on Malignant Mesothelioma

Artificial intelligence is creating a cumulative impact across malignant mesothelioma diagnosis, treatment planning, research, and surveillance. In radiology, AI-enabled image analysis has the potential to support detection of pleural abnormalities, quantify tumor burden, and assist response assessment on computed tomography and other imaging modalities, particularly where disease morphology is diffuse and difficult to measure. In pathology, computational tools can help support digital slide review, pattern recognition, and quality assurance, although expert pathologist confirmation remains essential because mesothelioma diagnosis requires careful integration of morphology, immunophenotype, and clinical context.

AI is also strengthening research and operational decision-making. Natural language processing can extract asbestos exposure histories, symptom patterns, pathology findings, and treatment outcomes from unstructured clinical records, enabling richer real-world evidence. Predictive analytics may support clinical trial matching, risk stratification, and resource planning for thoracic oncology programs. In public health, AI can assist in mapping exposure clusters, prioritizing inspection of aging infrastructure, and linking occupational history data with cancer registry information. The most reliable use cases will depend on validated datasets, transparent algorithms, data privacy safeguards, and clinical governance to reduce bias and avoid overreliance on unverified automated outputs.

Key Regional Insights for Malignant Mesothelioma

In Asia-Pacific, malignant mesothelioma trends are closely tied to heterogeneous asbestos policies, rapid urban redevelopment, legacy industrial exposure, and shipbuilding or shipbreaking activity in parts of the region. Australia and Japan have long-standing recognition of asbestos-related disease, while China, India, South Korea, and Southeast Asian economies face varying levels of diagnostic capacity, occupational surveillance, and remediation readiness. Growth in specialist oncology infrastructure is improving access to imaging, pathology, and systemic treatment, yet underdiagnosis remains a concern where occupational exposure histories are not consistently captured.

Europe has among the strongest policy frameworks, including broad asbestos restrictions across the European Union, but still faces a significant legacy burden due to historical industrial use. The United Kingdom, Germany, France, Italy, and Spain continue to manage cases linked to occupational exposure decades earlier, with specialized thoracic oncology and pathology capabilities supporting evidence-based care. Renovation of older buildings, energy-efficiency upgrades, and infrastructure redevelopment reinforce the need for asbestos surveys, certified abatement, and worker protection protocols.

North America has a mature malignant mesothelioma care environment supported by cancer registries, occupational safety rules, specialist thoracic oncology programs, and litigation-driven exposure documentation. The United States and Canada have extensive experience managing asbestos-related disease due to historical use in construction, manufacturing, shipyards, and military facilities. Clinical trial networks, immunotherapy adoption, and integrated palliative care are key strengths, while ongoing risk stems from older buildings and industrial sites containing asbestos materials.

Latin America presents a mixed picture, with Brazil and Mexico serving as important anchors for oncology services while regional access to specialist diagnostics and treatment remains uneven. Differences in asbestos regulation, worker protections, cancer registry completeness, and access to expert pathology influence disease identification and care continuity. Strengthening occupational medicine links with oncology referral pathways is central to improving malignant mesothelioma recognition across the region.

Africa faces substantial challenges, including limited diagnostic infrastructure, underreporting, variable asbestos regulation, and historical mining or industrial exposure in specific countries. Across African health systems, strengthening cancer registries, occupational health surveillance, pathology capacity, and safe asbestos abatement practices is central to improving malignant mesothelioma recognition and outcomes.

The Middle East shows rising relevance due to construction activity, industrial expansion, and reliance on migrant labor in certain markets, making occupational safety enforcement and asbestos management essential. GCC countries are investing in advanced healthcare infrastructure, which can support earlier diagnosis and access to oncology care when referral systems are well coordinated.

Key Group Insights for Malignant Mesothelioma

NATO member countries share overlapping concerns related to asbestos in military ships, bases, older facilities, and veteran exposure histories, making defense-related surveillance, remediation, exposure documentation, and healthcare access important elements of malignant mesothelioma policy and care. Coordinated approaches to facility inspection, veteran health monitoring, and safe maintenance of aging defense infrastructure can help reduce preventable exposure and support timely diagnosis.

The G7 has more established cancer care systems, broader access to immunotherapy and clinical trials, and stronger occupational health frameworks, but continues to carry a legacy asbestos burden in public buildings, homes, ships, and industrial assets. Across these high-income health systems, the key priority is integrating early referral, specialist pathology review, multidisciplinary thoracic oncology, and palliative care while maintaining rigorous asbestos control during renovation and demolition.

BRICS countries show diverse malignant mesothelioma dynamics, reflecting differences in asbestos production history, industrialization, regulatory maturity, and oncology infrastructure. Brazil, Russia, India, China, and South Africa each require stronger integration of occupational exposure records, cancer registry data, and specialist diagnostic services to support accurate disease recognition, particularly where asbestos exposure histories may be incomplete or underreported.

In the European Union, comprehensive asbestos restrictions, workplace safety directives, and cancer control initiatives provide a strong policy environment, yet the long latency of mesothelioma means cases continue to emerge from past exposures. The EU's focus on building renovation and energy efficiency also increases the importance of safe asbestos surveys, certified abatement, and workforce protection before redevelopment.

Within ASEAN, malignant mesothelioma priorities are shaped by industrial growth, construction activity, uneven asbestos regulation, and variable access to specialist cancer diagnostics. Countries with expanding urban infrastructure face increased need for asbestos identification, demolition controls, worker training, occupational disease surveillance, pathology networks, and exposure history documentation to reduce underdiagnosis across the group.

The GCC is characterized by substantial healthcare investment and ongoing construction and infrastructure development, which makes asbestos risk management and worker protection central to long-term disease prevention. Coordinated inspection programs, migrant worker health surveillance, and referral pathways to thoracic oncology specialists can improve malignant mesothelioma detection and management.

Key Country Insights for Malignant Mesothelioma

China's malignant mesothelioma landscape is shaped by large-scale industrial activity, urban redevelopment, and the need for stronger occupational exposure capture and specialist diagnostic standardization. The United States has a well-developed malignant mesothelioma care environment supported by specialist cancer centers, clinical trials, asbestos exposure documentation, and occupational safety oversight, though legacy asbestos in older buildings, shipyards, industrial sites, and military assets remains relevant. Japan has established recognition of asbestos-related disease and advanced oncology services, while continued monitoring is needed for historically exposed populations. India faces notable challenges related to asbestos use in building materials, worker protection, and access to pathology-confirmed diagnosis, particularly outside major cities.

Germany, the United Kingdom, France, Italy, and Spain continue to address legacy exposure through occupational health systems, pathology expertise, cancer registry infrastructure, and thoracic oncology services, while renovation of older buildings requires rigorous asbestos control. The United Kingdom has extensive experience with asbestos-related disease due to historical industrial and construction exposure, supported by specialist mesothelioma services. Germany and France benefit from structured occupational health frameworks and advanced oncology systems, while Italy and Spain continue to manage cases linked to historical industrial, construction, and shipyard exposure.

Australia has one of the most visible asbestos disease burdens globally due to past high asbestos use, with strong public awareness, compensation systems, and specialist care infrastructure. South Korea has strengthened asbestos controls and healthcare capacity, with ongoing importance placed on environmental exposure management, worker surveillance, and early referral. Canada has implemented strong asbestos restrictions and maintains public health attention on exposure prevention, while ongoing cases reflect past use in construction and mining-linked industries. Russia's profile is influenced by industrial history and the need for consistent exposure surveillance, cancer registration, and specialist access across a large geography.

Brazil has important oncology capacity in major urban centers, but regional disparities in diagnosis and treatment access influence malignant mesothelioma care pathways. Mexico faces the dual challenge of improving occupational surveillance and expanding timely access to specialist pathology and oncology services. Across all priority countries, consistent tissue diagnosis, accurate histologic classification, validated immunohistochemistry, appropriate molecular testing, and access to multidisciplinary care are decisive factors in improving malignant mesothelioma outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize earlier diagnosis by strengthening referral pathways from primary care, pulmonology, occupational medicine, and emergency departments to specialist thoracic oncology teams. Standardized diagnostic protocols should include detailed occupational and environmental exposure histories, high-quality imaging, expert pathology review, immunohistochemistry, and appropriate molecular testing to improve diagnostic confidence and treatment planning.

Healthcare systems and service providers should expand multidisciplinary mesothelioma programs that integrate medical oncology, thoracic surgery, radiation oncology, pathology, radiology, pulmonology, palliative care, rehabilitation, and psychosocial support. Diagnostics stakeholders should invest in validated digital pathology, AI-assisted image analysis, and real-world evidence platforms while maintaining clinical oversight and regulatory compliance. Public and private sector decision-makers should accelerate asbestos mapping, safe abatement, worker education, and exposure surveillance, especially in older buildings, shipyards, industrial facilities, mines, and redevelopment projects. Research leaders should improve clinical trial access, include underrepresented populations, and develop biomarker-driven strategies to support more personalized malignant mesothelioma treatment.

Research Methodology

This executive summary is based on a structured secondary research methodology using publicly available, verifiable sources such as cancer registry publications, occupational health guidance, peer-reviewed medical literature, clinical practice guidelines, government asbestos regulations, public health agency materials, and international cancer and labor health resources. Evidence was prioritized when it reflected established clinical consensus, documented asbestos exposure pathways, validated diagnostic practices, recognized treatment standards, or region-specific regulatory and healthcare infrastructure factors.

The research approach included cross-comparison of epidemiological patterns, asbestos policy environments, diagnostic standards, treatment pathway developments, and regional healthcare capacity. Insights were synthesized qualitatively to avoid unsupported quantification and to maintain compliance with the exclusion of market estimation, market sizing, market share, and forecasting. Particular emphasis was placed on malignant pleural mesothelioma, asbestos-related disease surveillance, pathology confirmation, multidisciplinary care, immunotherapy integration, artificial intelligence applications, and occupational exposure prevention.

Conclusion

Malignant mesothelioma remains a high-need oncology and occupational health challenge driven by long-latency asbestos exposure, diagnostic complexity, and aggressive disease biology. While regulatory action has reduced new asbestos use in many regions, the global burden persists because of legacy materials, uneven enforcement, and gaps in surveillance. Advances in immunotherapy, pathology, imaging, real-world evidence, and AI-enabled workflows are improving the ability to detect, classify, and manage the disease, but patient outcomes continue to depend heavily on early referral and access to experienced multidisciplinary teams.

The most effective strategic response combines clinical innovation with prevention-focused public health action. Stakeholders that invest in asbestos exposure control, specialist diagnostic capacity, equitable treatment access, validated digital tools, and robust occupational surveillance will be better positioned to address the continuing impact of malignant mesothelioma across mature and emerging healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Malignant Mesothelioma Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Pleural Mesothelioma
  • 7.3. Peritoneal Mesothelioma
  • 7.4. Pericardial Mesothelioma
  • 7.5. Tunica Vaginalis Mesothelioma

8. Malignant Mesothelioma Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Chemotherapy
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy
  • 8.5. Cell Therapy
  • 8.6. Gene Therapy
  • 8.7. Tumor Treating Fields
  • 8.8. Radiation Therapy

9. Malignant Mesothelioma Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Antifolate Agents
  • 9.3. Platinum-Based Agents
  • 9.4. Immune Checkpoint Inhibitors
  • 9.5. Monoclonal Antibodies
  • 9.6. Cell & Gene Therapies

10. Malignant Mesothelioma Market, by Line of Therapy

  • 10.1. Introduction
  • 10.2. First-Line Treatment
  • 10.3. Second-Line Treatment
  • 10.4. Third-Line and Later Therapy

11. Malignant Mesothelioma Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Cancer Centers
  • 11.4. Specialty Oncology Clinics
  • 11.5. Academic Medical Centers
  • 11.6. Research Institutes

12. Malignant Mesothelioma Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Malignant Mesothelioma Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Malignant Mesothelioma Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Amgen Inc.
  • 16.2. AstraZeneca PLC
  • 16.3. Atara Biotherapeutics, Inc.
  • 16.4. Bayer AG
  • 16.5. Boehringer Ingelheim International GmbH
  • 16.6. Bristol-Myers Squibb Company
  • 16.7. Candel Therapeutics, Inc.
  • 16.8. Cartesian Therapeutics, Inc.
  • 16.9. Eli Lilly and Company
  • 16.10. F. Hoffmann-La Roche AG
  • 16.11. GSK plc
  • 16.12. Merck & Co., Inc.
  • 16.13. Novocure Ltd.
  • 16.14. Pfizer Inc.
  • 16.15. SELLAS Life Sciences Group, Inc.
  • 16.16. Sensei Biotherapeutics, Inc.
  • 16.17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALIGNANT MESOTHELIOMA MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MALIGNANT MESOTHELIOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PLEURAL MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLEURAL MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PLEURAL MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERITONEAL MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PERITONEAL MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERITONEAL MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERICARDIAL MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERICARDIAL MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PERICARDIAL MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUNICA VAGINALIS MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUNICA VAGINALIS MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUNICA VAGINALIS MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TUMOR TREATING FIELDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUMOR TREATING FIELDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUMOR TREATING FIELDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIFOLATE AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIFOLATE AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIFOLATE AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PLATINUM-BASED AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLATINUM-BASED AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PLATINUM-BASED AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FIRST-LINE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FIRST-LINE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FIRST-LINE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SECOND-LINE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SECOND-LINE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SECOND-LINE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY ONCOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY ONCOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALTY ONCOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. JAPAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 195. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. AUSTRALIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. SOUTH KOREA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 246. GLOBAL MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025